Analysis of pharmacological interventions among hospitalised patients with COVID‑19: A focus on severe cases

Shinoda,Yasutaka; Ohashi,Kengo; Matsuoka,Tomoko; Yoshimura,Tomoaki

doi:10.3892/br.2022.1593

Analysis of pharmacological interventions among hospitalised patients with COVID‑19: A focus on severe cases

Authors:
- Yasutaka Shinoda
- Kengo Ohashi
- Tomoko Matsuoka
- Tomoaki Yoshimura
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan
Published online on: December 6, 2022 https://doi.org/10.3892/br.2022.1593
Article Number: 11

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Existing recommendations regarding pharmaceutical interventions for patients with coronavirus disease 2019 (COVID‑19) focus on outpatient, inpatient and post‑discharge care. However, there are no studies examining the actual activities of pharmacists in relation to hospitalised patients. The present study aimed to identify pharmacists' roles by analysing cases of pharmaceutical interventions, particularly for patients admitted to high‑care units. Pharmacological interventions were provided to patients with severe COVID‑19 or patients at high risk of severe disease in 2021. These pharmaceutical interventions were analysed and evaluated. Pharmacists also developed a COVID‑19 drug compatibility chart for use by care team members. In the present study, 54 patients were included, of which 33 were severe cases. A total of 28 patients (52%) received pharmacological interventions and 25 of them were severe cases. Out of 68 pharmacological interventions, interventions for antimicrobial agents were the most common (28 interventions), followed by nutrition and anti‑COVID‑19 drug‑related interventions. In addition, the need for interventions relating to drug compatibility was reduced by ~43% after the drug compatibility chart was implemented. In conclusion, pharmacists have a responsibility to improve the quality of pharmacotherapy for patients with COVID‑19. They should focus on creating specific pharmacotherapy tools for patients with COVID‑19 and supporting appropriate antimicrobial use for secondary bacterial infections.

View Figures

View References

1	Chu DK, Akl EA, Duda S, Solo K, Yaacoub S and Schünemann HJ: COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet. 395:1973–1987. 2020.PubMed/NCBI View Article : Google Scholar
2	Mistretta FA, Luzzago S, Molendini LO, Ferro M, Dossena E, Mastrilli F, Musi G and de Cobelli O: A guide for oncologic patient management during COVID-19 pandemic: The initial experience of an Italian oncologic hub with exemplificative focus on Uro-oncologic patients. Cancers (Basel). 12(1513)2020.PubMed/NCBI View Article : Google Scholar
3	Song Z, Hu Y, Ren Z, Wang G, Liu S, Zheng S, Yang L and Zhao R: Optimal management of the public and patients by pharmacists in the era of COVID-19: An evidence-based review and practical recommendations. Front Public Health. 9(758325)2022.PubMed/NCBI View Article : Google Scholar
4	Li M, Razaki H, Mui V, Rao P and Brocavich S: The pivotal role of pharmacists during the 2019 coronavirus pandemic. J Am Pharm Assoc (2003). 60:e73–e75. 2020.PubMed/NCBI View Article : Google Scholar
5	Nguy J, Hitchen SA, Hort AL, Huynh C and Rawlins MDM: The role of a Coronavirus disease 2019 pharmacist: An Australian perspective. Int J Clin Pharm. 42:1379–1384. 2020.PubMed/NCBI View Article : Google Scholar
6	Song Z, Hu Y, Zheng S, Yang L and Zhao R: Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience. Res Social Adm Pharm. 17:2027–2031. 2021.PubMed/NCBI View Article : Google Scholar
7	Gillespie L, Khan RZ, Stillson JE, Bunch CM, Shariff FS, Speybroeck J, Grisoli A, Schmidt MW, Phyu H, Jablonski J, et al: Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: A pilot prospective study. J Pharm Health Care Sci. 7(19)2021.PubMed/NCBI View Article : Google Scholar
8	Lat I, Paciullo C, Daley MJ, MacLaren R, Bolesta S, McCann J, Stollings JL, Gross K, Foos SA, Roberts RJ, et al: Position paper on critical care pharmacy services: 2020 Update. Crit Care Med. 48:e813–e834. 2020.PubMed/NCBI View Article : Google Scholar
9	Kondo M, Tanaka C, Tagami T, Nagano M, Sugaya K, Tagui N, Kaneko J, Kudo S, Kuno M, Unemoto K and Takase H: Utility of a compatibility chart for continuous infusions in the intensive care unit. J Nippon Med Sch. 89:227–232. 2022.PubMed/NCBI View Article : Google Scholar
10	Maison O, Tardy C, Cabelguenne D, Parat S, Ducastelle S, Piriou V, Lepape A and Lalande L: Drug incompatibilities in intravenous therapy: Evaluation and proposition of preventive tools in intensive care and hematology units. Eur J Clin Pharmacol. 75:179–187. 2019.PubMed/NCBI View Article : Google Scholar
11	Oda Y, Shimada M, Shiraishi S and Kurai O: Treatment and outcome of COVID-19 patients in a specialized hospital during the third wave: Advance of age and increased mortality compared with the first/second waves. JA Clin Rep. 7(85)2021.PubMed/NCBI View Article : Google Scholar
12	Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf MG, Lie-A-Huen L, Vroom MB and Smorenburg SM: On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: An intervention study. Crit Care. 14(R174)2010.PubMed/NCBI View Article : Google Scholar
13	Ahmed N, Khan M, Saleem W, Karobari MI, Mohamed RN, Heboyan A, Rabaan AA, Mutair AA, Alhumaid S, Alsadiq SA, et al: Evaluation of Bi-Lateral Co-Infections and antibiotic resistance rates among COVID-19 patients. Antibiotics (Basel). 11(276)2022.PubMed/NCBI View Article : Google Scholar
14	Cai Z, Yang Y and Zhang J: Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): A meta-analysis. BMC Public Health. 21(1505)2021.PubMed/NCBI View Article : Google Scholar
15	Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, Mirghaderi SP, Mahdiabadi S, Vahedi F, Saeidi S, et al: COVID-19 mortality and its predictors in the elderly: A systematic review. Health Sci Rep. 5(e657)2022.PubMed/NCBI View Article : Google Scholar
16	Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar
17	Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR and Daneman N: Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect. 26:1622–1629. 2020.PubMed/NCBI View Article : Google Scholar
18	Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, Matsunaga N, Kutsuna S, Sugiura W and Ohmagari N: Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 11(e047007)2021.PubMed/NCBI View Article : Google Scholar